Human breast cancer cell line xenografts as models of breast cancer - The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines

Breast Cancer Research and Treatment

Volumn 39, Issue 1, 1996, Pages 69-86

  Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell lines; Resistance; Xenografts

Indexed keywords

ANTIESTROGEN; ESTROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER CELL CULTURE; CANCER RESEARCH; CANCER TRANSPLANTATION; ENDOCRINOLOGY; GENE MUTATION; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOBIOLOGY; IMMUNOSURVEILLANCE; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC SURVEILLANCE; MICE; MICE, NUDE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029871171     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806079     Document Type: Review

References (146)

1. Steel GG, Courtenay VD, Peckham MJ: The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 47:1-15, 1983
2. Soule HD, Vasquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a human breast carcinoma. J Natl Cancer Inst 51:1409-1416, 1973
3. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ: Establishment and characterization of a cell line of human carcinoma origin. Eur J Cancer 15:659-670, 1979
4. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38:3352-3364, 1978
5. Clarke R: In vitro models of human breast cancer. In: Harris JR, Hellman S, Lippman ME, Morrow M (eds) Diseases of the Breast. J.B. Lippincott, Philadelphia, 1995, pp 245-261
6. Black MM, Zachrau RE, Hankey BF, Wesley M: Skin window reactivity to autologous breast cancer. An index of prognostically significant cell-mediated immunity. Cancer 62:72-83, 1988
7. Humphrey LJ, Singla O, Volenec FJ: Immunologic responsiveness of the breast cancer patient. Cancer 46:893-898, 1980
8. Strayer DR, Carter WA, Brodsky I: Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity. Breast Cancer Res Treat 7:187-192, 1986
9. An T, Sood U, Pietruk T, Cummings G: In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Am J Path 128:52-60, 1987
10. Contreras OO, Stoliar A: Immunologic changes in human breast cancer. Eur J Gynecol Oncol 9:502-514, 1988
11. Akimoto M, Ishii H, Nakajima Y, Iwasaki H: Assessment of host immune response in breast cancer patients. Cancer Detect Prev 9:311-317, 1986
12. Horst HA, Horny HP: Characterization and frequency distribution of lymphoreticular infiltrates in axillary lymph node metastases of invasive ductal carcinoma of the breast. Cancer 60:3001-3007, 1987
13. Bonilla F, Alvarez-Mon M, Merino F, de la Hera A: IL-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer 61:629-634, 1988
14. Levy SM, Herberman RB, Whiteside T, Sanzo K: Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med 52:73-85, 1990
15. Underwood JC, Giri DD, Rooney N, Lonsdale R: Immunophenotype of the lymphoid cell infiltrates in breast carcinomas of low oestrogen receptor content. Br J Cancer 56:744-746, 1987
16. Berry J, Green BJ, Matheson DS: Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminogluthemide. Cancer Immunol Immunother 24:72-75, 1987
17. Fridman R, Kibbey MC, Royce LS, Zain M, Sweeney TM, Jicha DL, Yannelli JR, Martin GR, Kleinman HK: Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with matrigel. J Natl Cancer Inst 83:769-774, 1991
18. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL: Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA 87: 6698-6702, 1990
19. Wheelock EF, Robinson MK: Endogenous control of the neoplastic process. Lab Invest 48:120-139, 1983
20. Blanchard DK, Kavanagh JJ, Sinoviks JG, Cavanagh D: Infiltration of IL-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. Cancer Res 48:6321-6327, 1988
21. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR: Role of NK cells in tumour growth and metastasis in beige mice. Nature 284:622-624, 1980
22. Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB: Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30:107-112, 1982
23. Richie JP: Abrogation of hematogenous metastases in a murine model by natural killer cells. Surgery 96:133-138, 1984
24. Vose BM, Moore M: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer 24:579-585, 1979
25. Mantovani A, Allavena P, Sessa C, Bolis G, Mangioni C: Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer 25:573-582, 1980
26. Andriole GL, Mule JJ, Hansen CT, Linehan WM, Rosenberg SA: Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J Immunol 135:2911-2913, 1985
27. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomena. Lysis of natural killer resistant solid tumour cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1827, 1982
28. Ebert EC, Roberts AI, Devereaux D, Nagase H: Selective immunosuppressive action of a factor produced by colon cancer cells. Cancer Res 50:6158-6161, 1990
29. Kelly PM, Davison RS, Bliss E, McGee JO: Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer 57:174-177, 1988
30. Key ME, Hoyer L, Bucana C, Hanna MG: Mechanisms of macrophage-mediated tumor cytolysis. Adv Exp Med Biol 146:265-311, 1982
31. Hibbs JB, Lambert LH, Remington JS: Control of carcinogenesis: a possible role for the activated macrophage. Science 177:9980-1000, 1972
32. Fidler IJ: Eradication of cancer metastasis by tumoricidal macrophages. Adv Exp Med Biol 233: 415-423, 1988
33. Fidler IJ, Schroit AJ: Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948:151-173, 1988
34. Whitworth PM, Pak CC, Esgro J, Kleinerman ES, Fidler IJ: Macrophages and cancer. Cancer Metastasis Rev 8:319-351, 1990
35. Meredino RA, Arena A, Liberto MC, Iannello D: Influence of sera from patients affected by neoplasia on some human macrophage functions. Cancer Detect Prev 12:73-80, 1988
36. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE: Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83:921-926, 1989
37. Acero R, Polentarutti N, Bottazzi B, Alberti S, Ricci MR, Bizzi A, Mantovani A: Effect of hydrocortisone on the macrophage content, growth and metastasis of transplanted murine tumors. Int J Cancer 33:95-105, 1984
38. Shultz LD: Single gene models of immunodeficiency diseases. In: Wu B, Zheng J (eds) Immune-deficient Animals in Experimental Medicine. Karger, Basel, 1989, pp 19-26
39. Pantelouris EM: Absence of thymus in a mutant mouse. Nature 217:370-371, 1968
40. Rygaard J, Povlsen CO: Heterotransplantation of a human malignant tumour to "nude" mice. Acta Path Microbiol Scand 77:758-760, 1969
41. Maruo K, Ueyama Y, Hioki K, Saito M, Nomura T, Tamaoki N: Strain-dependent growth of a human carcinoma in nude mice with different genetic backgrounds: selection of nude mouse strains useful for anticancer agent screening system. Exp Cell Biol 50:115-119, 1982
42. Kindred B: The inception of the response to SRBC by nude mice injected with various doses of congenic or allogeneic thymus cells. Cell Immunol 17:277-284, 1975
43. Jacobson EB, Caporale LH, Thorbecke GJ: Effect of thymus cell injections on germinal center formation in lymphoid tissues of nude (thymusless) mice. Cell Immunol 13:416-430, 1974
44. Guy-Grand D, Griscelli C, Vassalli P: Peyer's patches, gut IgA, plasma cells and thymic function: study in nude mice bearing thymic grafts. J Immunol 115:361-364, 1975
45. De Sousa M, Pritchard H: The cellular basis of immunological recovery in nude mice after thymus grafting. Immunology 26:769-776, 1974
46. Weisz-Carrington P, Schrater AF, Lamm ME, Thorbecke GJ: Immunoglobulin isotypes in plasma cells of normal and athymic mice. Cell Immunol 44:343-351, 1979
47. Manning JK, Reed ND, Jutila JW: Antibody response to Escherichia coli lipopolysaccharide by congenitally thymusless (nude) mice. J Immunol 108:1470-1472, 1972
48. Herberman RB, Nunn ME, Holden HT, Staal S, Djeu JY: Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. Int J Cancer 19:555-564, 1977
49. Kiessling R, Klein E, Wagzell H: "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to phenotype. Eur J Immunol 72:2130-2134, 1975
50. Hasui M, Saikawa Y, Miura M, Takano N, Ueno Y, Yachie A, Miyawaki T, Taniguchi N: Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (Scid) and athymic (Nude) mice. Cell Immunol 120: 230-239, 1989
51. Johnson WJ, Balish E: Macrophage function in germ-free, athymic (nu/nu) mice and conventional flora (nu/+) mice. J Reticuloendothel Soc 28:55-66, 1980
52. Roder JC: The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol 123:2168-2173, 1979
53. Roder JC, Duwe AK: The beige mutation in the mouse selectively impairs natural killer cell function. Nature 278:451-453, 1979
54. Karre K, Klein GO, Kiessling R, Klein G, Roder JC: Low natural in vivo resistance to syngeneic leukemias in natural killer-deficient mice. Nature 284:624-626, 1980
55. Karre K, Klein GO, Kiessling R, Klein G, Roder JC: In vitro NK-activity and in vivo resistance to leukemia: studies of beige, beige/nude and wild type hosts on C57BL background. Int J Cancer 26:789-797, 1980
56. Clark EA, Shultz LD, Pollack SB: Mutations that influence natural killer (NK) cell activity. Immunogenetics 12:601-613, 1981
57. Hioki K, Maruo K, Suzuki S, Kato H, Shimamura K, Saito M, Nomura T: Studies on beige-nude mice with low natural killer cell activity. 1. Introduction of the bg gene into nude mice and the characteristics of beige-nude mice. Lab Animals 21:72-77, 1987
58. Kincade PW: Defective colony formation by B lymphocytes from CBA/N and C3H/HeJ mice. J Exp Med 145:249-263, 1977
59. Ahmed A, Scher I, Sharrow SO, Smith AH, Paul WE, Sachs DH, Sell KV: B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J Exp Med 145:101-110, 1977
60. Perlmutter RM, Nahm M, Stein KE, Slack J, Zitron I, Paul WE, Davie JM: Immunoglobulin subclass-specific immunodeficiency in mice with an X-linked B-lymphocyte defect. J Exp Med 149:993-998, 1979
61. Scher I: The CBA/N mouse strain: experimental model illustrating the influence of the X-chromosome on immunity. Adv Immunol 33:1-71, 1982
62. Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765-4769, 1989
63. Azar HA, Hansen CT, Costa J: N:NIH(S)II-nu/nu mice with combined immunodeficiency: a new model for human tumor heterotransplantation. J Natl Cancer Inst 65:421-430, 1980
64. Karagogeos D, Rosenberg N, Wortis HH: Early arrest of B cell development in nude, X-linked immune-deficient mice. Eur J Immunol 16:1125-1130, 1986
65. Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530, 1983
66. Komatsu K, Kubota N, Gallo M, Okumura Y, Lieber MR: The scid factor on human chromosome 8 restores V(D)J recombination in addition to double-strand break repair. Cancer Res 55:1774-1779, 1995
67. Schuler W, Weiler IJ, Schuler A, Phillips RA, Rosenberg N, Mak TW, Kearney JF, Perry RP, Bosma MJ: Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell 46:963-972, 1986
68. Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosma GC, O'Toole M, Bosma MJ: Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 132:1804-1808, 1984
69. Custer RP, Bosma GC, Bosma MJ: Severe combined immunodeficiency (scid) in the mouse. Pathology, reconstitution, neoplasms. Am J Path 120:464-477, 1985
70. Mueller BM, Reisfeld RA: Potential use of the scid mouse as a host for human tumors. Cancer Metastasis Rev 10:193-200, 1991
71. Malynn BA, Blackwell TK, Fulop GM, Rathbun GA, Furley AJW, Ferrier P, Heinke LB, Phillips RA, Yancopoulos GD, Alt FW: The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism. Cell 54:453-460, 1988
72. Quimby FW: Immunodeficient Rodents. A Guide to their Immunobiology, Husbandry, and Use. National Academy Press, Washington DC, 1989
73. Dorshkind K, Pollack SB, Bosma MJ: Natural killer (NK) cells are present in mice with severe combined immunodeficiency (SCID). J Immunol 134:2911-2913, 1985
74. Ikeda S, Neyts J, De Clercq E: Host defense mechanisms against murine cytomegalovirus infection induced by poly I:C in severe combined immune deficient (SCID) mice. Proc Soc Exp Biol Med 207: 191-196, 1994
75. Bancroft GJ, Kelly JP: Macrophage activation and innate resistance to infection in SCID mice. Immunobiology 191:424-431, 1994
76. Reed ND, Hall-Stoodley L, Shultz L: Mast cell production by scid/scid mice: in vivo and in vitro studies. In: Wu B, Zheng J (eds) Immune-deficient Animals in Experimental Medicine. Karger, Basel, 1989, pp 63-67
77. Fodstad O: Tumorigenicity and dissemination of human tumors in congenitally immune-deficient mice. J Natl Cancer Inst 83:1419-1420, 1991
78. Kubota N, Yamaguchi H, Watanabe M, Yamamoto T, Takahara T, Takeuchi T, Furukawa T, Kase S, Kodaira S, Ishibiki K: Growth of human tumor xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today 23:375-377, 1993
79. Oakley CS, Welsch MA, Zhai YF, Chang CC, Could MN, Welsch CW: Comparative abilities of nude mice and severe combined immune deficient (SCID) mice to accept transplants of induced rat mammary carcinomas: enhanced transplantation efficiency of those rat mammary carcinomas that have elevated expression of neu oncogene. Int J Cancer 53:1002-1007, 1993
80. Xie X, Brünner N, Jensen G, Albrectsen J, Gotthardsen B, Rygaard J: Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. Clin Exp Metastasis 10:201-210, 1992
81. Fodstad O, Hansen CT, Cannon GB, Statham CN, Lichenstein GR, Boyd MR: Lack of correlation between natural killer cell activity and tumor growth control in nude mice with different immune defects. Cancer Res 44:4403-4408, 1984
82. Bosma MJ, Carroll AM: The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 9:323-350, 1991
83. Clarke R, Dickson RB: Animal models of tumor onset, growth and metastasis. In: Bertino JR (ed) Molecular Biology of Cancer, Vol. 1. Academic Press, San Diego (in press)
84. Seibert K, Shafie SM, Triche TJ, Whang-Peng JJ, O'Brien SJ, Toney JH, Huff KK, Lippman ME: Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res 43:2223-2239, 1983
85. Cattanach B, Iddon A, Charlton H, Chiappa S, Fink G: Gonadotropin releasing hormone deficiency in a mutant mouse with hypogonadism. Nature 269:338-340, 1977
86. Masom A, Hayflick J, Zoeller R, Young W, Philips H, Nickolics K, Seeberg PA: A deletion truncating the gonadotropin-releasing gene is responsible for hypogonadism in the hpg mouse. Science 234:1366-1371, 1986
87. Charlton H, Speight A, Halpin D, Bramwell A, Sheward W, Fink G: Prolactin measurements in normal and hypogonadal (hpg) mice: developmental and experimental studies. Endocrinology 113:545-548, 1983
88. Beamer WG, Shultz KL, Tennent B, Shultz LD: Granulosa cell tumorigenesis in genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors. Cancer Res 53:3741-3746, 1993
89. Screpanti I, Santoni A, Gulino A, Herberman RB, Frati L: Estrogen and antiestrogen modulation of mouse natural killer activity and large granular lymphocytes. Cell Immunol 106:191-202, 1987
90. Seaman WE, Blackman MA, Gindhart TD, Roubinian JR, Loeb JM, Talal N: β-estradiol reduces natural killer cells in mice. J Immunol 121:2193-2198, 1978
91. Hanna N, Schneider M: Enhancement of tumor metastases and suppression of natural killer cell activity by β-estradiol treatment. J Immunol 130:974-980, 1983
92. Seaman WE, Talal N: The effect of 17β-estradiol on natural killing in the mouse. In: Herberman RB (ed) Natural Cell-mediated Immunity Against Tumors. Academic Press, New York, 1980, pp 765-777
93. Shafie SM, Grantham FH: Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67:51-56, 1981
94. Welsch CW, Swim EL, McManus MJ, White AC, McGrath CM: Estrogen induced growth of human breast cancer cells (MCF-7) in athymic nude mice is enhanced by secretions from transplantable pituitary tumor. Cancer Lett 14:309-316, 1981
95. Clarke R, Brünner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME, Dickson RB: Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc Natl Acad Sci USA 86: 3649-3653, 1989
96. Clarke R, Brünner N, Thompson EW, Glanz P, Katz D, Dickson RB, Lippman ME: The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J Endocrinol 122:331-340, 1989
97. Blumenthal RD, Jordan JJ, McLaughlin WH, Bloomer WD: Animal modeling of human breast tumors: limitations in the use of estrogen pellet implants. Breast Cancer Res Treat 11:77-78, 1988
98. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
99. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in athymic nude mice: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189-1196, 1987
100. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel JA, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 53:2168-2177, 1993
101. Friedl A, Jordan VC: Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. Eur J Cancer 30A: 1559-1564, 1994
102. Brünner N, Boulay V, Fojo A, Freter C, Lippman ME, Clarke R: Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53:283-290, 1993
103. Brünner N, Svenstrup B, Spang-Thompsen M, Bennet P, Nielsen A, Nielsen JJ: Serum steroid levels in intact and endocrine ablated Balb/c nude mice and their intact litter mates. J Steroid Biochem 25:429-432, 1986
104. Jones DY, Schatzkin A, Green SB, Block G, Brinton LA, Ziegler RG, Hoover R, Taylor PR: Dietary fat and breast cancer in the National Health and Nutrition Examination Survey I epidemiologic follow-up study. J Natl Cancer Inst 79:465-471, 1987
105. Thompson EW, Brünner N, Torri J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS, Clarke R: The invasive and metastatic properties of hormone-independent and hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 11:15-26, 1993
106. Clarke R, Skaar T, Baumann K, Leonessa K, James MR, Lippman J, Thompson EW, Freter C, Brünner N: Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 31:237-248, 1994
107. Clarke R, Lippman ME: Antiestrogen resistance: mechanisms and reversal. In: Teicher BA (ed) Drug Resistance in Oncology. Marcel Dekker, New York, 1992, pp 501-536
108. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53:3229-3232, 1993
109. Bronzert DA, Greene GL, Lippman ME: Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 117:1409-1417, 1985
110. Belani CP, Pearl P, Whitley NO, Aisner J: Tamoxifen withdrawal response: report of a case. Arch Intern Med 149:449-450, 1989
111. Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet i:36, 1989
112. Stein W, Hortobagyi GN, Blumenschein GR: Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol 22:45-46, 1983
113. Nawata H, Chong MT, Bronzert D, Lippman ME: Estradiol independent growth of a subline of MCF-7 human breast cancer cells in culture. J Biol Chem 256:6895-6902, 1981
114. Nawata H, Bronzert D, Lippman ME: Isolation and characterization of a tamoxifen resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem 256:5016-5021, 1981
115. van den Berg HW, Clarke R: Preliminary characterization of a tamoxifen resistant variant of the oestrogen responsive human breast cancer cell line ZR-75-1. Br J Cancer 52:421 1985
116. van den Berg HW, Lynch M, Martin J, Nelson J, Dickson GR, Crockard AD: Characterization of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and stability of the resistant phenotype. Br J Cancer 59:522-526, 1989
117. Clarke R, Brünner N: Cross resistance and molecular mechanisms in antiestrogen resistance. Endocr Related Cancer 2:59-72, 1995
118. Johnston SRD, Saccanti-Jotti G, Smith IE, Newby J, Dowsett M: Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer. Endocr Related Cancer 2:105-110, 1995
119. MDR1: ascites models of human breast cancer. Br J Cancer (in press)
120. Yee D, Kozelsky TW, Allred DC, Brünner N, Chen S-C, Woo SLC: Adenoviral in vivo gene transfer using a xenograft ascites model of human breast cancer. Breast Cancer Res Treat 32(suppl):77, 1994
121. Nicholson GL, Gallick GE, Sphon WH, Lembo TM, Tainsky MA: Transfection of activated c-HarasEJ/pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification of spontaneous metastatic and cell surface properties. Oncogene 7: 1127-1135, 1992
122. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH: A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone independent tumor growth. Mol Endocrinol 2:886-892, 1988
123. Zyad A, Bernard J, Clarke R, Tursz T, Brockhaus M, Chouaib S: Human breast cancer cross-resistance to TNF and adriamycin: relationship to MDR1, MnSOD and TNF gene expression. Cancer Res 54:825-831, 1994
124. Doroshow JH, Akman S, Esworthy S, Chu FF, Burke T: Doxorubicin resistance is conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. Free Radic Res Commun 12-13 Pt 2:779-781, 1991
125. Iwamoto S, Takeda K: Possible cytotoxic mechanisms of TNF in vitro. Hum Cell 3:107-112, 1990
126. Batist G, Tuple A, Sinha BK, Katki AG, Myers CE, Cowan KH: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261:15544-15549, 1986
127. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE: Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49:3844-3848, 1989
128. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748-1756, 1990
129. Clarke R, Currier SJ, Kaplan O, Boulay V, Lovelace E, Pastan I, Gottesman MM, Dickson RB: Role of MDR-1 expression in the hormone responsiveness of MCF-7 human breast cancer cells. Proc Am Assoc Cancer Res 32:366, 1991
130. Brünner N, Thompson EW, Spang-Thomsen M, Rygaard J, Dano K, Zwiebel JA: lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer 28A: 1989-1995, 1992
131. Price JE, Polyzos A, Zhang RD, Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717-721, 1990
132. Rose DP, Hatala MA, Connolly JM, Rayburn J: Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in nude mice. Cancer Res 53:4686-4690, 1993
133. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG: Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res 53:2178-2187, 1993
134. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat (this issue)
135. Schackert G, Price JE, Bucana CD, Fidler IJ: Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int J Cancer 44:892-897, 1989
136. Clarke R, Dickson RB, Lippman ME: Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12:1-23, 1992
137. Meyvisch C: Influence of implantation site on formation of metastases. Cancer Metastasis Rev 2:295-306, 1983
138. Volpe JPG, Milas L: Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases. Clin Exp Metastasis 8:381-389, 1990
139. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48: 6863-6871, 1988
140. Kozlowski JM, Fidler IJ, Campbell D, Xu Z-L, Kaighn ME, Hart IR: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44:3522-3529, 1984
141. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1:216-223, 1987
142. Sainsbury JRC, Nicholson JA, Angus B, Farndon JR, Malcolm AJ, Harris AL: Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer 58:458-460, 1988
143. Sainsbury JRC, Farndon JR, Nedham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet i:1398-1402, 1987
144. Castronovo V, Taraboletti G, Liotta LA, Sobel ME: Modulation of laminin receptor expression by estrogen and progestins in human breast cancer cell lines. J Natl Cancer Inst 81:781-788, 1989
145. Thompson EW, Paik S, Brünner N, Sommers C, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150:534-544, 1992
146. Butler WB, Kirkland WL, Jorgensen TL: Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochem Biophys Res Commun 90:1328-1334, 1979